- Home
- RIGL vs BHK Comparison
RIGL vs BHK Comparison
Compare RIGL & BHK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RIGL | BHK |
|---|---|---|
| Founded | 1996 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 628.4M | 665.2M |
| IPO Year | 2000 | N/A |
Fundamental Metrics
Financial Performance| Metric | RIGL | BHK |
|---|---|---|
| Price | $25.93 | $9.04 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $45.67 | N/A |
| AVG Volume (30 Days) | ★ 365.0K | 327.4K |
| Earning Date | 03-03-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 8.34% |
| EPS Growth | ★ 1867.68 | N/A |
| EPS | ★ 19.48 | 1.03 |
| Revenue | ★ $294,282,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $12.23 | N/A |
| P/E Ratio | ★ $1.34 | $8.87 |
| Revenue Growth | ★ 64.15 | N/A |
| 52 Week Low | $15.50 | $9.03 |
| 52 Week High | $52.24 | $11.00 |
Technical Indicators
Market Signals| Indicator | RIGL | BHK |
|---|---|---|
| Relative Strength Index (RSI) | 27.05 | 26.96 |
| Support Level | $18.14 | $9.03 |
| Resistance Level | $31.26 | $9.72 |
| Average True Range (ATR) | 1.39 | 0.08 |
| MACD | -0.19 | -0.03 |
| Stochastic Oscillator | 10.63 | 3.57 |
Price Performance
Historical ComparisonAbout RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.
About BHK Blackrock Core Bond Trust
Blackrock Core Bond Trust is a closed-ended management investment company. Its objective is to provide current income and capital appreciation. The trust seeks to achieve its investment objective by investing, under normal market conditions, at least 75% of its managed assets in bonds that are investment-grade quality at the time of investment. The trust, under a normal market scenario, will invest in a range of bonds, including corporate bonds, U.S. government and agency securities, and mortgage-related securities.